October 22, 2016 8:11 AM ET


Company Overview of Avid Radiopharmaceuticals, Inc.

Company Overview

Avid Radiopharmaceuticals, Inc. develops molecular imaging agents for the medical management of chronic human diseases by identifying the first stages of pathological change. The company was founded in 2004 and is based in Philadelphia, Pennsylvania. As of December 20, 2010, Avid Radiopharmaceuticals, Inc. operates as a subsidiary of Eli Lilly and Company.

3711 Market Street

7th Floor

Philadelphia, PA 19104

United States

Founded in 2004





Key Executives for Avid Radiopharmaceuticals, Inc.

Founder, Chief Executive Officer, President and Director
Chief Scientific Advisor and Chairman of the Scientific Advisory Board
Chief Medical Officer
Vice President of Clinical Development
Vice President of Chemical Development and Manufacturing
Compensation as of Fiscal Year 2016.

Avid Radiopharmaceuticals, Inc. Key Developments

Avid Radiopharmaceuticals, Inc. Presents at 1st Annual Neuroscience BioPartnering & Investment Forum, Feb-23-2016 11:05 AM

Avid Radiopharmaceuticals, Inc. Presents at 1st Annual Neuroscience BioPartnering & Investment Forum, Feb-23-2016 11:05 AM. Venue: The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St, 40th Floor (D Elevator Bank), New York, NY 10007, United States. Speakers: Mark A. Mintun, Chief Medical Officer.

Eli Lilly and Company and Avid Radiopharmaceuticals, Inc. Announce Financial Commitment and Continued Scientific Partnership

Eli Lilly and Company and Avid Radiopharmaceuticals, Inc. announced financial commitment and continued scientific partnership to support the recently established Imaging Dementia 'Evidence for Amyloid Scanning (IDEAS) Study'. The IDEAS Study will assess the clinical usefulness and value in using an amyloid brain positron emission tomography (PET) scan in certain situations when evaluating Alzheimer's disease (AD) and other dementias. Amyvid™ (Florbetapir F-18 Injection), Lilly's FDA-approved radioactive PET diagnostic agent for the estimation of beta-amyloid neuritic plaque density in the brain, will be one diagnostic agent available for use in the study. Manufactured in and distributed from 30 radiopharmacy facilities throughout the United States, Amyvid is currently supplied to a robust network of PET imaging sites by Siemens' PETNET Solutions and Cardinal Health. Amyvid for intravenous use is supplied in 10 mL, 30 mL, or 50 mL multidose vials containing 500-1900 MBq/mL Florbetapir F-18.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Avid Radiopharmaceuticals, Inc., please visit www.avidrp.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.